SciBX: Science-Business eXchange Contents: August 30 2012, Volume 5 / Issue 34

TABLE OF CONTENTS August 30 2012, Volume 5 / Issue 34 Analysis Cover Story Translational Notes Tools The Distillery: Therapeutics Cancer Cardiovascular disease Endocrine/metabolic disease Infectious disease Neurology Ophthalmic disease The Distillery: Techniques Assays and screens Disease models Drug delivery Drug platforms Markers BioPharma Dealmakers The June 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities within the academic and vaccine fields in the U.S and abroad. This week, find out about how you can collaborate with Scil Proteins.   SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Dissociating the effects of A2A agonism Kai-Jye Lou doi:10.1038/scibx.2012.887 Researchers in Germany have dissociated the anti-inflammatory effects of adenosine A2A receptor agonists from their hemodynamic effects and are determining a specific inflammation-related indication to pursue with their lead molecule. Full Text | PDF Translational Notes Top The cost of reproducibility Tim Fulmer doi:10.1038/scibx.2012.888 The newly launched Reproducibility Initiative could help researchers validate the key findings of their preclinical research programs and improve the chances of attracting investors and partners. However, precise details regarding funding, standards of reproducibility and potential conflicts of interest have yet to be worked out. Full Text | PDF Tools Top deCode-ing autism Lev Osherovich doi:10.1038/scibx.2012.889 General media coverage of deCode's recent findings about the potential relationship between paternal age, single mutation rates and incidence of neuropsychiatric diseases has masked the more fundamental insights gained by the researchers into the paternal origin of de novo genetic variation in human populations in general. Full Text | PDF Eliminating teratomas Lauren Martz doi:10.1038/scibx.2012.890 A UCSD team has developed a genetic method to prevent embryonic stem cell therapies from forming cancerous teratomas following transplantation. The method was safe in mice, although questions remain about whether the genetic modifications will raise safety and regulatory concerns in patients. Full Text | PDF Distillery: Therapeutics Cancer Top Notch 1 (NOTCH1); microRNA-181a (miR-181a); miR-181b-1 doi:10.1038/scibx.2012.891 Mouse and cell culture studies suggest inhibiting miR-181a and miR-181b-1 could help treat NOTCH1 pathway–driven T cell ALL. Full Text | PDF Aurora kinase A (AURKA; Aurora-A) doi:10.1038/scibx.2012.892 A study in cell culture and in mice suggests AURKA inhibitors could help treat acute megakaryoblastic leukemia (AMKL), a rare form of AML. Full Text | PDF Fibroblast growth factor receptor (FGFR); FGFR3; transforming acidic coiled-coil containing protein 1 (TACC1); TACC3 (ERIC1) doi:10.1038/scibx.2012.893 Mouse studies suggest FGFR kinase inhibitors could help treat a subtype of glioblastoma driven by FGFR-TACC fusion proteins. Full Text | PDF DAN domain family member 5 (DAND5; COCO) doi:10.1038/scibx.2012.894 Mouse and patient sample studies suggest inhibiting COCO could help prevent breast cancer from metastasizing to the lung. Full Text | PDF Hypoxia-inducible factor prolyl hydroxylase 2 (EGLN1; HIF-PH2; PHD2) doi:10.1038/scibx.2012.895 Mouse studies suggest PHD2 inhibitors could help improve the efficacy of chemotherapies. Full Text | PDF Integrin β3 (GPIIIa; CD61) doi:10.1038/scibx.2012.896 Mouse studies identified a humanized single-chain antibody against an epitope of GPIIIa, dubbed GP11a, that could help prevent pulmonary metastasis in cancer. Full Text | PDF Nicotinamide phosphoribosyltransferase (NAMPT) doi:10.1038/scibx.2012.897 Cell line studies suggest carborane-based small molecule NAMPT inhibitors could help treat cancer. Full Text | PDF Wingless-type MMTV integration site family member 16B (WNT16B) doi:10.1038/scibx.2012.898 Human tissue and mouse studies suggest inhibiting stromal WNT16B could help treat cancer. Full Text | PDF Chemerin; chemokine-like receptor 1 (CMKLR1; ChemR23) doi:10.1038/scibx.2012.899 Patient and mouse studies suggest increasing chemerin signaling could help treat melanoma. Full Text | PDF Cardiovascular disease Top DNA; RNA doi:10.1038/scibx.2012.900 Mouse and in vitro studies identified a nucleic acid–binding polymer that could help prevent thrombosis. Full Text | PDF Endocrine/metabolic disease Top Neutrophil elastase (NE; ELA-2) doi:10.1038/scibx.2012.901 In vitro and mouse studies suggest inhibiting NE could help treat diabetes. Full Text | PDF Infectious disease Top Influenza A virus hemagglutinin (HA); influenza B HA doi:10.1038/scibx.2012.902 In vitro and mouse studies suggest human mAbs could be used to treat or prevent influenza A and influenza B virus infections. Full Text | PDF Neurology Top GABAA receptor doi:10.1038/scibx.2012.903 Cell culture and mouse studies suggest compounds mimicking both nitric oxide (NO) and γ-aminobutyric acid (GABA) could help treat AD. Full Text | PDF Neural precursor cell expressed developmentally downregulated 4 E3 ubiquitin protein ligase (NEDD4; NEDD4-1) doi:10.1038/scibx.2012.904 In vitro and mouse studies suggest inhibiting NEDD4-1 could help treat neurodegenerative diseases. Full Text | PDF Galectin-1 (LGALS1) doi:10.1038/scibx.2012.905 In vitro and mouse studies suggest LGALS1 could help treat MS. Full Text | PDF Ephrin-A5 (EFNA5; AL-1) doi:10.1038/scibx.2012.906 Mouse studies suggest inhibiting EFNA5 could help promote recovery from stroke. Full Text | PDF Unknown doi:10.1038/scibx.2012.907 Rat studies suggest 3-pentylbenzo[c]thiophen-1(3H)-one could help treat stroke. Full Text | PDF Ophthalmic disease Top Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3) doi:10.1038/scibx.2012.908 Mouse studies suggest inhibiting RIPK signaling could help treat retinitis pigmentosa. Full Text | PDF Distillery: Techniques Assays and screens Top Prenatal genome sequencing doi:10.1038/scibx.2012.909 A study in pregnant women suggests fetal whole-genome sequencing could help detect chromosomal abnormalities. Full Text | PDF Disease models Top Transgenic mouse model for schizophrenia doi:10.1038/scibx.2012.910 Transgenic mice with astrocyte-specific overexpression of human heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32) could be a useful model for schizophrenia and other neurodevelopmental and neurodegenerative diseases. Full Text | PDF Drug delivery Top Nonviral DNA nanoparticles for ocular gene therapy to treat Stargardt's disease doi:10.1038/scibx.2012.911 Mouse studies suggest nonviral DNA nanoparticles could be used for ocular gene therapy to help treat Stargardt's disease, a retinal degenerative disorder caused by mutations in ATP-binding cassette sub-family A member 4 (ABCA4; ABCR). Full Text | PDF Drug platforms Top Anandamide–small interfering RNA conjugates for targeting neuronal and immune cells doi:10.1038/scibx.2012.912 Anandamide-siRNA conjugates that silence gene expression in neuronal and immune cells could be useful for treating immunological and neurological diseases. Full Text | PDF Markers Top Mutations linked to paternal age doi:10.1038/scibx.2012.913 A human genetic study suggests mutations in the sperm of older fathers could influence disease in their offspring. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.